The short answer
Semaglutide activates the GLP-1 receptor. Tirzepatide activates the GLP-1 and GIP receptors. Retatrutide activates all three: GLP-1, GIP and glucagon. That is the core difference, and it is why retatrutide is called a triple agonist.
Receptor targets describe how a peptide works. On their own they do not show which one performs better, and no single comparison settles that.
Receptor targets side by side
- Semaglutide: GLP-1 receptor agonist. A licensed medicine.
- Tirzepatide: dual GIP and GLP-1 receptor agonist. A licensed medicine.
- Retatrutide: triple GIP, GLP-1 and glucagon receptor agonist, developed by Eli Lilly under the code LY3437943. Still investigational.
What each receptor does
GLP-1 is an incretin hormone released by the gut after eating. In research it is linked with glucose dependent insulin release, slower gastric emptying and appetite regulation in the brain.
GIP is the second main incretin hormone. It also influences insulin release, and its role in body weight and fat metabolism is still an active research question.
Glucagon normally raises blood glucose. In metabolic research it is also studied for effects on energy expenditure and liver fat, which is why combining it with GLP-1 activity is of interest.
Where the evidence stands
Semaglutide and tirzepatide have completed large clinical programmes and are licensed medicines. Retatrutide is still investigational. Phase 2 results were published in the New England Journal of Medicine in 2023, and the developer has since reported phase 3 results. It has reported plans to file with the US FDA in the first quarter of 2027. See [[retatrutide trial results explained|/blog/retatrutide-trial-results]].
Why trial comparisons need care
Trials differ in population, length, dose schedules and statistical methods, so percentage figures from separate trials are not directly comparable. The same trial can give different figures depending on how it is analysed. Head to head trials answer the question properly, and results are best read from the published papers rather than headlines.
Key terms explained
- Receptor: a protein on the surface of a cell that responds to a signalling molecule.
- Agonist: a molecule that activates a receptor.
- Incretin: a gut hormone released after eating that influences insulin release and appetite.
- Triple agonist: a single molecule designed to activate three receptors.
Licensed names and status
Semaglutide is marketed as Ozempic and Wegovy. Tirzepatide is marketed as Mounjaro and Zepbound. These are licensed medicines. Retatrutide has no brand name and no marketing authorisation.
Why add glucagon activity?
In research models, glucagon receptor activity raises energy expenditure and influences liver fat metabolism. On its own it would also raise blood glucose, so the idea behind a triple agonist is that GLP-1 and GIP activity offset that effect while the glucagon component adds a separate energy balance pathway. This is the rationale researchers describe. Clinical results are what test it.
How the receptors are studied in the laboratory
In cell based assays, receptor activation is commonly measured through downstream signalling such as cyclic AMP accumulation. Researchers compare potency at each receptor, because potency can differ between them. Binding, signalling and receptor trafficking are assessed separately.
What this means for laboratory research
In the laboratory, retatrutide is used as a reference triple agonist to study how combined receptor activity shapes signalling, metabolism and energy balance. Cambridge Health supplies [[retatrutide research vials|/retatrutide]] and the [[RetaPen multidose research pen|/retapen]] for laboratory research only. Clinical results describe a medicine given under medical supervision and do not describe research materials.
References and evidence context
HCPLive, Retatrutide meets phase 3 weight loss endpoints in 2 obesity trials, 2026
Clinical research concerns the investigational material used in those trials. It does not establish equivalence, approval or suitability for human use of products supplied here.
Frequently asked questions
Is retatrutide stronger than tirzepatide?
That cannot be answered from receptor targets alone. Retatrutide adds glucagon receptor activity, but the trials were designed separately and use different populations and methods. Each study should be read on its own terms.
Is retatrutide a GLP-1 drug?
It activates the GLP-1 receptor, so it is a GLP-1 receptor agonist, but it also activates the GIP and glucagon receptors. That is why it is described as a triple agonist.
What is the difference between tirzepatide and retatrutide?
Tirzepatide activates the GIP and GLP-1 receptors. Retatrutide adds the glucagon receptor.
Is retatrutide approved?
Not at the time of writing. It is investigational, and the developer has reported plans to file with the FDA in the first quarter of 2027.
Important information
Research use only. Not a medicine, not a supplement, not approved for human or animal use.
Cambridge Health™ does not provide usage, dosage, reconstitution or administration guidance for any product. Product information on this page is provided for research and educational context only.
- Supplied strictly for laboratory and analytical research use. Not for human or animal consumption.
- No medical advice, treatment guidance or personal use recommendations are provided.
- Buyers are solely responsible for ensuring that the purchase, import, handling and use of research materials is lawful in their jurisdiction.
Supplied for laboratory research use only. Not a licensed medicine and not approved for human or animal use.
Related
- ProductRetatrutide research vials
- GLP-1 researchRetatrutide Trial Results Explained
- GLP-1 researchWhat Is Retatrutide? Research Overview
- ProductRetaPen retatrutide research pen
- MechanismHow Does Retatrutide Work? The Triple Agonist Mechanism Explained
- Trial dataRetatrutide Side Effects Reported in Clinical Trials
Enquire about research supply
Cambridge Health supplies retatrutide research vials and the RetaPen for laboratory research. Submit a purchase request to discuss availability.